LAUSR

Introduction Preeclampsia (PE) is associated with an increased cardiovascular risk in later life, especially in women after early-onset PE. We and others have shown that activating antibodies against angiotensin II receptor type 1 (AT1-) are present in women with PE, even after pregnancy. Further, regulatory (auto-) antibodies against G-coupled receptors (GPCR) have been shown to contribute to cardiovascular disease. Hypothesis We tested the hypothesis that regulatory autoantibodies’ titers are elevated in women with a history of early-onset PE and correlate to physiological parameters and clinical outcomes. Methods We investigated data from PREVFEM (Preeclampsia Risk EValuation in FEMales) retrospective matched case-control study, which was performed in Zwolle, The Netherlands, from 2008 until 2010. All women registered in the early PE database as well as an equal number of age-matched females without PE from the regular obstetric database in the same time period (1991–2007) were invited to participate in the PREVFEM study. Autoantibodies against AT1-, β1-adrenergic receptors, endothelin I receptor A (ETAR), protease-activated receptor 1 (PAR1) and C-X-C3 chemokine binding receptors (CXC3R) were determined in 609 samples (306 cases and 303 controls) by using commercially available ELISA (Celltrend, Luckenwalde, Germany). Results The titer levels of AT1-, β1-, ETAR-, PAR1- and CXC3R-autoantibodies were not significantly different between control and former PE groups 10 years after index pregnancy. Former PE women showed a significantly higher prevalence of hypertension (43% vs. 17%, p  Discussion Regulatory autoantibodies against GPCR do not identify women at higher risk for cardiovascular disease 10 years after early-onset PE. The need to search for biomarkers identifying women at risk before cardiovascular symptoms is continuing.